Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Astex and MSD Announce Collaboration

Astex and MSD Announce Collaboration

10th August 2023

The collaboration’s goal is to identify small biological compounds to act as a tumor-shrinking protein for use in cancer therapy

As part of the partnership, Astex will use its molecule-based drug identification technology to pick out proteins which aid in reducing tumors while also supplying MSD with the primary compounds for more advanced development and preclinical testing.

In the meantime, MSD has been provided exclusive worldwide authorization to explore, establish, and promote collaboration candidates.

The chairman and CEO of Astex, Harren Jhoti stated “Astex is applying its fragment-based drug discovery capability to design and generate small molecule modulators tailored to a wide range of potentially important therapeutic targets.” He goes on to say, “This new cooperation expands on our previous fruitful relationship and enables us to combine our experience and assets with MSD’s broad cancer capabilities.”

Astex will be provided with a $35 million initial payment and will be able to receive milestone bonuses based on specific measurable achievements. These will amount to about $500 million for every project, as well as structured income from revenues of goods resulting from the collaboration.

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.